Strides Pharma Science
STAR NSE
Strides Pharma Science
HealthcareNSE: STAR BSE: 532531 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹10,969 Cr
Volatility
High Risk
P/E Ratio
17.78
EBITDA
₹1,076 Cr
Return on Equity
18.24%
Debt to Equity
0.57
Book Value
₹337.15
52W High
₹1,231
52W Low
₹768.65
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 20.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%
Weaknesses
3- Stock is trading at 3.51 times its book value
- The company has delivered a poor sales growth of 7.94% over past five years.
- Promoters have pledged 38.1% of their holding.
Growth Rate
Revenue Growth
8.33% lower than
3Y
Net Income Growth
40.33% lower than
3Y
Cash Flow Change
2.65% higher than
3Y
ROE
15.22% higher than
3Y
ROCE
-1.27% lower than
3Y
EBITDA Margin (Avg.)
15.3% lower than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoAI opinion · based on fundamentals
Risk high
Strides Pharma Science (market cap ₹10,347 Cr, PE 18.1x) has delivered strong profit growth over the past 3-5 years with a notable 3-year ROE of 57%, but faces headwinds from decelerating sales growth (TTM at 6%) and a sharp TTM profit decline of -84%. Promoter pledging at 27.3% adds governance risk to an otherwise improving return profile.
Bull Case 7
- Strong 3-year ROE of 57% indicates efficient capital allocation and high returns on shareholder equity
- Compounded profit growth of 71% CAGR over 3 years demonstrates significant earnings recovery
- 5-year compounded profit growth of 21% CAGR reflects sustained long-term earnings expansion
- Stock CAGR of 76% over 3 years suggests strong market re-rating driven by improving fundamentals
- PE ratio of 18.1x is reasonable for a pharma company with 20%+ ROE in the last year
- 10-year compounded profit growth of 16% CAGR shows the business has scaled profitability over a full cycle
- Dividend yield of 0.35% indicates the company has initiated shareholder returns alongside growth
Bear Case 8
- TTM compounded profit declined -84%, signalling a sharp and severe earnings reversal in the most recent period
- Promoters have pledged 27.3% of their holding, raising corporate governance and forced-selling risk
- 5-year sales CAGR of only 7.94% reflects poor top-line momentum for a mid-cap pharma company
- Stock trades at 3.34x book value, which is elevated given the recent earnings collapse
- TTM sales growth has decelerated to just 6%, below the 10-year average of 5% CAGR on a compounded basis
- Tax rate appears low, which may not be sustainable and could compress future net margins if normalized
- 10-year stock CAGR of only 8% suggests long-term wealth creation has been inconsistent despite recent rally
- Debt-to-equity ratio is undisclosed, limiting visibility into the company's leverage and financial risk profile
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago Neutral 2
- Sells Pivot Path stake Jun 27
Strides Pharma sold its majority stake in Pivot Path to Ascent Capital for Rs 1,000 million. Pivot Path will be reclassified as an associate company.
- Unrelated STAR ETF launched Jun 9
BlackRock launched the iShares Space Technologies UCITS ETF under the ticker STAR on Jun 9, 2026, tracking space technology stocks. This is unrelated to Strides Pharma and concerns only a shared ticker symbol in European markets.
TL;DR: A quiet period for Strides Pharma with no material positive or negative catalysts. The Pivot Path divestiture is a minor portfolio restructuring event. The STAR ETF news is unrelated to the company. No clear directional trend emerging from recent newsflow.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 930 | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Expenses | 796 | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 |
| Operating Profit | 134 | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 14% | 11% | 13% | 16% | 18% | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% |
| Other Income | 3 | -129 | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 76 | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 60 | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| PBT | 0 | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | 3025% | -5% | 23% | 55% | 1% | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% |
| Net Profit | -9 | -149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS in Rs | -0.79 | -14.54 | 5.4 | 1.98 | 365 | 7.81 | 9.54 | 8.91 | 10.8 | 13.84 | 21.93 | 13.77 | 17.02 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,004 |
| Expenses | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,338 | 2,779 | 3,201 | 3,544 | 3,362 | 3,763 | 3,933 | 4,070 |
| Operating Profit | 229 | 374 | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 | 935 |
| OPM % | 19% | 13% | 19% | 14% | 9% | 15% | 16% | -4.3% | 3.9% | 14% | 18% | 19% | 19% |
| Other Income | 874 | 63 | 291 | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3,313 | 124 | 193 |
| Interest | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 | 172 |
| Depreciation | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 | 210 |
| PBT | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3,675 | 669 | 746 |
| Tax % | 15% | 31% | 12% | 1% | -9% | 27% | 11% | -27% | -21% | 45% | 2% | 14% | — |
| Net Profit | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 | 634 |
| EPS in Rs | 142 | 12.15 | 44.71 | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 390 | 60.34 | 66.56 |
| Div. Payout % | 76% | 41% | 10% | 3% | 8% | 345% | 8% | 0% | -7% | -33% | 1% | 8% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
| Reserves | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 | 3,015 |
| Borrowings | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | 1,758 |
| Other Liabilities | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | 1,941 |
| Total Liabilities | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
| Fixed Assets | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | 2,101 |
| CWIP | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 447 |
| Investments | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 |
| Other Assets | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | 3,967 |
| Total Assets | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Investing | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Financing | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| Free Cash Flow | -157 | -293 | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
| CFO/OP | 61 | 40 | 66 | 61 | 59 | 60 | 60 | 199 | -30 | 128 | 77 | 84 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 132 | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 107 | 96 | 97 |
| Inventory Days | 135 | 149 | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 235 | 236 | 305 |
| Days Payable | 153 | 188 | 221 | 188 | 299 | 259 | 323 | 260 | 220 | 178 | 190 | 244 |
| Cash Conversion Cycle | 102 | 92 | 120 | 71 | 160 | 119 | 128 | 168 | 165 | 164 | 141 | 157 |
| Working Capital Days | -91 | 6 | -122 | -4 | -70 | -70 | -22 | -28 | -11 | -19 | 24 | 38 |
| ROCE % | 57% | 8% | 11% | 16% | 2% | 5% | 8% | -5% | 0% | 7% | 15% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Strides Pharma Science insights
71 extracted metrics + investor summaries across FY10–FY27.
Documents
1
Completion Of USFDA Inspection At The Company''s Formulations Facility At Alathur
11 Sep - USFDA completed cGMP inspection at Alathur facility; issued Form 483 with three observations. 11 Sep - USFDA completed cGMP inspection at Alathur facility; issued Form 483 with three observations.
2
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015
10h - Board meets May 18, 2026 to approve FY26 audited results and consider final dividend. 10h - Board meets May 18, 2026 to approve FY26 audited results and consider final dividend.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8h - Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. 8h - Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2 Apr - Certificate As per Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended March 31, 2026 2 Apr - Certificate As per Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended March 31, 2026
5
Closure of Trading Window
25 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 FY2026 results; board meeting date TBA. 25 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 FY2026 results; board meeting date TBA.
Frequently Asked Questions about Strides Pharma Science
What does Strides Pharma Science Ltd do?
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new market...
Where is Strides Pharma Science Ltd (STAR) listed?
Strides Pharma Science Ltd trades as STAR on the NSE and under code 532531 on the BSE.
Which sector does Strides Pharma Science Ltd belong to?
Strides Pharma Science Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has a market capitalisation of ₹10,969 Cr, which places it in the Mid Cap band.
What is the PE ratio of Strides Pharma Science Ltd?
Strides Pharma Science Ltd trades at a PE ratio of 17.78, against a book value of ₹337.15 per share.
What is the 52-week high and low of Strides Pharma Science Ltd?
Over the last 52 weeks Strides Pharma Science Ltd has traded between ₹768.65 and ₹1,231.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd has a dividend yield of 0.41%.
What is the Return on Equity (ROE) of Strides Pharma Science Ltd?
Strides Pharma Science Ltd reported a return on equity of 18.24%. Its debt-to-equity ratio is 0.57.
Company Information
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
Website strides.com
CEO Mr. Arun Kumar Pillai B.Com.
Employees 3,301
Listed 2000-02-02
Face Value ₹ 10
Issued Size 9,21,72,714
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/STAR.md for Strides Pharma Science Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.